		Туре:	Document reference:	Manual Class	sification:	
Waika	ato District Health Board	Drug Guideline	2947	Waikato DHB Drug Guidelines		
Title:	Octreotide for n	eonates		Effective date 26 Janu	e: ary 2022	
Facilitator sign/date	Authorised sign/date	Authorised	sign/date	Version: 1	Page: 1 of 3	
Kerrie Knox Pharmacist	Jutta van den Boom Clinical Director NICU	John Barna I Chair Med	John Barnard Document Chair Medicines & Therapeutics Document			

© Waikato DHB, February 2022

BRIEF ADMINISTRATION GUIDE

For detailed information refer to The New Zealand Formulary for Children octreotide monograph

Indications: • chylothorax

Route: Intravenous

- Supplied as octreotide 500 microgram in 1 mL vial Note: use the short acting formulation only and ensure concentration is confirmed before dilution (also available as 50 microgram and 100 microgram in 1 mL)
 - o Octreotide is not licensed in NZ for chylothorax
 - o pH is 3.9 4.5
- **Dose**: Initially 1 microgram/kg/hour, then titrate upwards as necessary based on reduction in chyle production. Maximum dose 10 microgram/kg/hour.

Note: avoid abrupt withdrawal

Preparation and administration

Compatible fluids: sodium chloride 0.9% (preferred as octreotide inhibits release of insulin and affects blood glucose regulation), glucose 5%

Continuous IV infusion

 Select the concentration of octreotide required based on the weight of the infant and in the context of any fluid restrictions (refer to Appendix for assistance) and dilute the appropriate volume of octreotide injection using compatible fluid in accordance with the table below:
 *Ensure concentration of octreotide vial matches that in table or make adjustments if different

Final Octreotide Concentration	10 microgram/mL	25 microgram/mL		
Volume of octreotide (500* microgram/ 1 mL)	1 mL	1 mL		
Volume of compatible fluid	49 mL	19 mL		
Total volume	50 mL	20 mL		

 Administer at the prescribed rate by continuous IV infusion using a syringe driver with Guardrails settings

Rate (mL/hr) = $\frac{\text{Dose (microgram/kg/hr) x Weight (kg)}}{2}$

Concentration (microgram/mL)

Monitoring

- Chyle volumes
- Blood glucose (hyperglycaemia more common, but hypoglycaemia can occur)
- Hepatic function, baseline then weekly

Storage

- Store unopened injections in a refrigerator between 2 and 8°C. Remove ampoule and wait until it is at room temperature before using
- Discard any unused solution left in the ampoule
- Diluted solution is stable for 24 hours in sodium chloride 0.9%

Waikato District Health Board	Document reference: 2947	Effective date: 26 Jan 202	Expiry date	e: 2025	Page: 2 of 3
Title: Octreotide for neonates		Type: Drug Guideline	Version: 1	Authoris	sing initials:

Competency for Administration

This procedure is carried out by, or under, the direct supervision of a registered nurse/registered midwife who holds current Waikato DHB Generic Medicine Management and IV certification plus Guardrails competency (if administering IV) as well as Neonatal specific competency NCV/NAC (if administering via CVAD).

Guardrails Information

Octreotide will be Guardrail profiled on the CC pump for NICU. Following are the guardrail limits:

Guardrails Drug Name	Octreotide
Concentration (mcg/ml)	
Minimum	4
Maximum	50
Dose rate (mcg/kg/hour)	
Default	1
Soft minimum	0.9
Soft maximum	10
Hard max	10.1

References

- Truven Health Analytics Inc. Pediatrics and Neofax®. Octreotide monograph. Accessed 25.5.2021. Available from: <u>http://www.micromedexsolutions.com.</u>
- New Zealand Formulary for Children (NZFC) v107. Octreotide. Accessed 25.5.2021. Available from https://www.nzfchildren.org.nz
- Phelps SJ, Hagemann TM, Lee KR, Thompson AJ. The Teddy Bear Book: Pediatric Injectable Drugs. 11th edition. American Society of Health-System Pharmacists; 2018.
- Canterbury DHB Neonatal Drug Information Sheet Octreotide. Available from http://www.edu.cdhb.health.nz
- The Royal Children's Hospital Melbourne. Paediatric Injectable Guidelines. Accessed 2.9.2021. Available from https://pig.rch.org.au
- South Australia Neonatal Medication Guideline Octreotide. Available from http://www.sahealth.sa.gov.au
- King Edward Memorial Hospital Neonatal Medication Protocol Octreotide. Available from http://www.kemh.health.wa.gov.au
- Queensland Health Clinical Guideline Octreotide 2019. Available from http://health.gld.gov.au
- Australian Injectable Drugs Handbook 8th edition. Society of Hospital Pharmacists of Australia. 2020.

Note: Printed copies are only valid on the day of printing – they are not controlled and may not be the current version in use. Please refer to the online version.

Disclaimer: This document has been developed by Waikato District Health Board specifically for its own use. Use of this document and any reliance on the information contained therein by any third party is at their own risk and Waikato District Health Board assumes no responsibility whatsoever.

Waikato District Health Board	Document reference: 2947	Effective date: 26 Jan 202	Expiry date 2 26 Jan	2025	Page: 3 of 3
Title: Octreotide for neonates		Type: Drug Guideline	Version: 1	Authoris	sing initials:

Appendix

Infusion tables

Table 1: Infusion rates when using octreotide concentration**10 microgram/mL**(most useful for neonates $\leq 2 \text{ kg}$)

Rate (mL/hr)	0.1	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1
Weight (kg)	Approximate microgram/kg/hour									
0.5	2	4	6	8	10	12	14	16	18	20
1	1	2	3	4	5	6	7	8	9	10
1.5	0.7	1.3	2	2.7	3.3	4	4.7	5.3	6.0	6.7
2	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5.0
2.5	0.4	0.8	1.2	1.6	2	2.4	2.8	3.2	3.6	4
3	0.3	0.7	1	1.3	1.7	2	2.3	2.7	3	3.3
3.5	0.3	0.6	0.9	1.1	1.4	1.7	2	2.3	2.6	2.9
4	0.3	0.5	0.8	1	1.3	1.5	1.8	2	2.3	2.5
4.5	0.2	0.4	0.7	0.9	1.1	1.3	1.6	1.8	2	2.2
5	0.2	0.4	0.6	0.8	1	1.2	1.4	1.6	1.8	2

Table 2: Infusion rates when using octreotide concentration 25 microgram/mL(most useful for neonates > 2 kg)

Rate (mL/hr)	0.1	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1
Weight (kg)	Approximate microgram/kg/hour									
1	2.5	5	8	10	13	15	18	20	23	25
1.5	1.7	3.3	5	6.7	8.3	10	11.7	13.3	15	16.7
2	1.3	3	4	5	6	8	9	10	11	13
2.5	1.0	2	3	4	5	6	7	8	9	10
3	0.8	1.7	2.5	3.3	4.2	5	5.8	6.7	7.5	8.3
3.5	0.7	1.4	2.1	2.9	3.6	4.3	5	5.7	6.4	7.1
4	0.6	1.3	1.9	2.5	3.1	3.8	4.4	5	5.6	6.3
4.5	0.6	1.1	1.7	2.2	2.8	3.3	3.9	4.4	5	5.6
5	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5